Pfizer (PFE.US) will announce its Q2 financial results.
According to the Zhī tōng finance app, Pfizer (PFE.US) will announce its Q2 financial results on Tuesday, July 30. Zacks expects Pfizer's Q2 revenue to be $13.22 billion, a year-on-year increase of 3.8%; EPS is $0.46, a year-on-year decrease of 31.3%.
Analysts' expectations for Pfizer's Q2 EPS have been raised by 1.17% compared to the past 30 days.
The company's EPS has exceeded market expectations for the past four quarters.
As the impact of the epidemic dissipates, the rapid and significant decline in revenue related to the new crown drug has put Pfizer in a position of lacking "core" growth. Investors are closely watching Pfizer's core products, especially the performance of cancer and vaccine products other than new crown drugs.
In addition, Pfizer is pushing forward with the development of a weight-loss drug, trying to enter the multi-billion dollar weight-loss drug market. The company earlier this month said that danuglipron, a once-daily oral weight-loss drug, will enter Phase II trials in the second half of this year after clearing scientific hurdles in a small study. If the drug is successful, it will enter the final stage of development.
Pfizer has predicted that oral weight-loss drugs will eventually account for about one-third of the weight-loss drug market. Analysts predict that by the end of this decade, sales of weight-loss drugs will reach $130 billion.
Since the beginning of this year, Pfizer's stock price has risen by nearly 12%, but it has lagged behind the S&P 500 index by more than 14%.